TGA concedes it failed to prevent growing number of blood toxicity cases linked to Vitamin B6 | 7.30

Key Concepts:

• Vitamin B6 toxicity (specifically from pyridoxine, pyridoxal, or pyridoxamine)
• Neuropathy (nerve damage) as a result of B6 toxicity
• Therapeutic Goods Administration (TGA) regulation of supplements in Australia
• Supplement labeling and consumer health literacy
• Class action lawsuit against supplement manufacturers (Blackmores Group)
• Adverse event reporting and data inadequacy

Vitamin B6 Toxicity: A Growing Concern

A pathology lab is experiencing a surge in vitamin B6 tests, with a significant proportion (a quarter) showing concerning levels. The number of tests has nearly doubled recently, indicating a growing problem. High B6 levels are leading to neuropathy in patients, causing symptoms like tingling, numbness, burning, or weakness, particularly in the hands and feet. Early intervention is crucial as nerve damage, especially to sensory nerves, may be irreversible.

Sources and Prevalence of B6 Overexposure

While vitamin B6 is essential and naturally found in many foods, its manufactured forms (pyridoxine, pyridoxal, or pyridoxamine) added to medicines, energy drinks, diet shakes, and supplements are causing issues. In Australia, over 1,500 supplements contain B6, with 80% exceeding the recommended daily amount. The widespread use of multiple supplements likely contributes to hundreds of thousands of Australians having B6 levels far above recommended levels.

Regulatory Response and Perceived Shortcomings

The Therapeutic Goods Administration (TGA) tightened B6 regulations in 2022, but many believe these measures are insufficient. The TGA is being "very careful" in its regulatory approach, aiming to meet community needs. However, the changes implemented a few years ago have not effectively reduced B6 toxicity rates.

Legal Action and Patient Experiences

Nick Mann is leading a potential class action against Blackmores Group, a major supplement manufacturer, due to B6 toxicity cases. The number of people contacting him about the class action has been overwhelming. Phil Estasio, a patient, experienced a decline in health after taking Blackmore Super Magnesium Plus (containing 50mg of B6) for three months, despite assuming B vitamins were beneficial. His B6 levels were seven times higher than the safe upper limit. He felt betrayed by choosing a product he believed would help his health.

TGA Recommendations and Industry Response

Following pressure, the TGA issued recommendations based on an investigation that found the benefits of high-dose B6 to be negligible, labeling inconsistent and confusing, and dose management beyond the average consumer's health literacy. Companies will be required to clarify labels, and supplements with over 50mg of B6 will be stored behind the counter.

Ongoing Concerns and Future Actions

While the TGA considers this a good interim decision, concerns remain that even 50mg can lead to overdose over time, especially with multiple supplements. Pharmacists are advised to double-check the safety of complementary medicines. Some argue for a lower threshold (e.g., 25mg or 10mg) due to neuropathy cases reported at lower doses, as is the case in Europe. The TGA acknowledges reports of B6 toxicity at low levels that don't seem dose-related in some patients, but doesn't believe regulatory changes would protect that "very small number of people." The TGA will make its final decision by next February, giving the complementary medicine sector a year to comply with changes.

Data Limitations and Future Outlook

The TGA maintains that B6-related incidents are rare based on sales data compared to adverse event reports. However, the TGA admits that its adverse event database is inadequate and doesn't accurately reflect the true scale of the problem in the community. The TGA's increased interest is seen as a positive step towards a reasonable solution in the coming years.

Notable Quotes:

• Pathology Lab Representative: "Sometimes we talk to doctors who don't believe they think it's a clerical error. The result is that high. And we have to say, 'No, no, it's it's real. You need to sort it out.'"
• Doctor: "The sooner you act on it, the better. Nerves don't always recover, especially sensory nerves if they're damaged."
• Phil Estasio: "Felt betrayed. you know, I went down this big spiral of just not being able to process that, you know, I'd been responsible for a dip in my own health by choosing something that I thought was going to help."
• TGA Representative: "I am aware that there are reports of vitamin B6 toxicity at low levels but they don't seem to be in some patients they don't seem to be related to dose."
• TGA Representative: "It's sufficient to say that our database of adverse events doesn't necessarily reflect the true incidence of what's happening in the community."

Technical Terms and Concepts:

• Pyridoxine, Pyridoxal, Pyridoxamine: Different forms of Vitamin B6 commonly found in supplements and fortified foods.
• Neuropathy: Nerve damage, often causing tingling, numbness, burning, or weakness.
• Therapeutic Goods Administration (TGA): Australia's regulatory agency for therapeutic goods, including medicines, medical devices, and supplements.
• Adverse Event Reporting: The process of reporting negative health outcomes potentially related to medications or supplements.
• Health Literacy: The degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions.

Synthesis/Conclusion:

The video highlights a growing concern regarding vitamin B6 toxicity in Australia, primarily due to excessive supplementation. Despite regulatory efforts, the problem persists, with many individuals experiencing neuropathy. The TGA's response is viewed as a step in the right direction, but concerns remain about the adequacy of current regulations, labeling practices, and data collection. The potential class action lawsuit underscores the severity of the issue and the need for more effective measures to protect consumers from B6-related health risks.